TransCon PTH for treating hypoparathyroidism


featured image

TransCon PTH is in clinical development for the treatment of hypoparathyroidism (HP). HP can be caused when the parathyroid glands do not produce enough parathyroid hormone (PTH). This causes low blood calcium levels (hypocalcaemia).

Interventions: TransCon PTH
Indications: Hypoparathyroidism
Year: 2023

TransCon PTH is in clinical development for the treatment of hypoparathyroidism (HP). HP can be caused when the parathyroid glands do not produce enough parathyroid hormone (PTH). This causes low blood calcium levels (hypocalcaemia). The parathyroid glands are very small glands situated in the neck just behind the thyroid gland and they control calcium levels in the bloodstream to make sure one does not have too little or too much calcium. HP can happen after neck surgery (thyroidectomy) or because of rare genetic conditions. The main symptoms of HP include fatigue, tingling, pins and needle sensations, and muscle cramps. Treatment of HP has been challenged by the limited number of effective medicinal products and side-effects associated with them.